CYCART

Dead / Abandoned — Abandoned — failure to respond (as of 15 Jun 2023)

What this means for you

This application is over — abandoned 16 May 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
90765924
Mark type
Stylized text
Filed
10 Jun 2021
Abandoned
16 May 2023
Attorney of record
CAMILLE M. MILLER

Goods and services

  • Class 001 — Chemicals: Bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research; placental-derived cells, chimeric antigen receptor (CAR) T cells, and placental-derived T cells with a chimeric antigen receptor (CAR), all for use in scientific, laboratory and medical research
  • Class 005 — Pharmaceuticals: Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, placental-derived cells, umbilical cord cells, placental-derived T cells, chimeric antigen receptor (CAR) T cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; human amniotic membrane and human chorionic membrane intended for subsequent implantation; human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological products for medical use, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen; biological tissue intended for use as a wound covering and burn dressing; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds and burns; and written instructional materials distributed in connection with the aforesaid goods; biological products for medical use, namely, placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen

Owner

Prosecution history

  • 18 Aug 2023 — EXPARTE APPEAL TERMINATED
  • 18 Aug 2023 — EXPARTE APPEAL DISMISSED AS MOOT
  • 15 Jun 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
  • 15 Jun 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
  • 15 Jun 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
  • 31 May 2023 — ASSIGNED TO EXAMINER
  • 14 Feb 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
  • 14 Feb 2023 — NON-FINAL ACTION E-MAILED
  • 14 Feb 2023 — NON-FINAL ACTION WRITTEN
  • 16 Dec 2022 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
  • 16 Dec 2022 — EX PARTE APPEAL-INSTITUTED
  • 16 Dec 2022 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
  • 16 Dec 2022 — EXPARTE APPEAL RECEIVED AT TTAB
  • 16 Jun 2022 — NOTIFICATION OF FINAL REFUSAL EMAILED
  • 16 Jun 2022 — FINAL REFUSAL E-MAILED

View this trademark record on Marksy